Abstract: The embodiments herein discloses a composition and method for the synthesis of an effervescence producing tablet for reducing and eliminating a mouth odor and oral staining caused by ingested beverages and food. The method comprises mixing excipients, disintegrating agents, flavor and sweetener in a V-blender. The lubricant is added V-blender to obtain a mixture. The mixture is compressed on tablet press equipment with a round tooling. The tablets are packaged in a foil pouch. The “excipients” in the effervescent tablet composition are malic acid, sorbitol, potassium bi-carbonate, microcrystalline cellulose, sodium chloride, sodium carbonate and magnesium oxide. The malic acid react with potassium bicarbonate or sodium bicarbonate or sodium carbonate to form an effervescence reaction to induce tablet disintegration, provide a pleasant sensation in the mouth, and to clean a wine stain in the mouth.

Abstract: The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering budiodarone to reduce atrial fibrillation (AF) episode duration and an anticoagulant (AC). According to some methods of the invention, the average AF episode duration can be reduced to less than about 24, 5, 3 or 1 hour(s), and the maximum AF episode duration may be reduced to less than about 20, 10 or 5 hours. According to some methods of the invention, the reduced stroke rate upon administration of budiodarone and AC is less than the age-adjusted overall stroke rate. Further, some methods provide that patients who were refractory to one or more anti-arrhythmic drugs prior to administration of budiodarone may also be treated. Some methods provide for prevention of atrial remodeling and others provide for the reversal of atrial remodeling, including methods to quantify the reversal of atrial remodeling.

Abstract: A dietary supplement comprising powdered ingredients: zeolite powder: 70%-5%, dehydrated seaweed: 5%-25%, seawater extract: 5%-10% Chlorella: 5%-10% and Spirulina: 5%-10%, methods of making and using the composition.

Abstract: A capsule slurry including at least one coacervated capsule and at least 10 wt % humectant is disclosed. The humectant may be sorbitol, glycerin, polyethylene glycol, propylene glycol, xylitol, erythritol and/or betaine.

Abstract: A solid dispersion of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the solid dispersion are provided herein. Also, a pharmaceutical composition comprising a solid dispersion of N4-(4-([1,2,4]triazolo[1,5-?]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and uses thereof are provided herein.

Abstract: The present invention generally relates to dosage forms for oral administration including one or more gelling agents. In particular, the present invention is directed to gelling agent-based dosage forms that are easily administered and taken, or swallowed. The present invention is also directed to gelling agent-based dosage forms that exhibit relatively low syneresis, are thermally stable, exhibit substantially constant active ingredient concentration, and/or exhibit one or more advantageous rheological properties. In particular, the present invention is directed to such gels containing one or more omega-3 fatty acids. The gelling agent-based dosage forms of the present invention are suitable for administration of a relatively large dose of active ingredient. The gelling agent-based dosage forms of the present invention are also suitable for administration of multiple active ingredients.

Abstract: A cosmetic water-based ink containing at least one acryl-based polymer, at least one polymeric ionic thickener, at least one anionic or amphoteric-ionic surfactant, at least one material in particle form and at least one non-ionic surfactant, wherein the non-ionic surfactant is a compound which contains between 4 and 8 units of PEG or PPG and a C6-C20 fatty acid residue.

Abstract: A composition including 0.5-40 weight % vegetable extract, 30-90 weight % sugar and 0.5-30 weight % phospholipid for cosmetic, pharmaceutical or dietary uses.

Abstract: The present invention refers to a modified release pharmaceutical composition comprising desvenlafaxine or salts thereof, a release rate modifying system that controls the release of active agent(s) in both acidic and basic environments. A process of making and method of using the above-described composition is also disclosed.

Abstract: This invention provides a carrageenan mixture comprising about 60% to about 95% by weight of iota-carrageenans and about 5% to about 25% by weight of lambda-carrageenans, which is useful as an ingredient of a cosmetic formulation such as a fully natural hair styling gel being free from synthetic polymers.

Abstract: Agglomerates comprising calcium-hydrocolloid-composite materials and at least one sugar alcohol, as well of methods for preparing the agglomerates and various applications thereof.

Abstract: There is provided a compound of Formula (I) and salts thereof, where R1 is an oxime or an alkylated oxime; the alkylated oxime comprises a linear or branched alkyl group of length C1 to C5; and R2 are each independently (a) an unsubstituted or substituted linear or branched alkyl group of chain length C1-7, (b) an aryl substituted alkyl group, where the aryl group is substituted, (c) an alkoxy substituted alkyl group, where the alkoxy group is substituted by a methoxy group or an alkoxy group substituted with an alkoxy group, or (d) an H atom, where the substituents in (a) and (b) are hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, nitro, oxo or fluoro groups. The compounds may be used as a medicament.

Abstract: The disclosure provides, in part, compositions and methods for producing emulsions. In certain embodiments, emulsions of the disclosure can be used for the detection of inflammation and cell tracking using MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell members, in vivo. In certain embodiments, emulsions can be used as an artificial blood substitute.

Abstract: A topical skin cream composition having as one of its main objects to provide a topical skin cream having anti-biotic properties to prevent infection in wounds. In addition the combination of components in the composition help combat the effects of aging as well as help ward off psoriasis.

Abstract: A multi-functional, foaming male shaving product comprising of (i) a surfactant blend consisting of an alkyl isethionate and a glyceryl alkanoate, wherein the ratio, by weight of alkyl isethionate to glyceryl alkanoate is between 5:1 to 8:1, (ii) a copolymer of acrylamide and iallyldimethylammonium chloride; (iii) a combination of a yeast extract, an algae extract, an extract of Chondrus crispus, and glucosamine hydrochloride; and (iv) a continuous self-foaming agent containing a volatile hydrofluoroether.

Abstract: A method for treating a neoplastic disorder in a subject includes administering to the neoplastic cells a neoplastic cell-sensitizing composition including a poly(ethylene oxide)-poly(propylene oxide) copolymer. The poly(ethylene oxide)-poly(propylene oxide) copolymer can sensitize the neoplastic cells to hyperthermia. Energy can be applied to the neoplastic cells to heat and ablate the cells.

Abstract: A dialysis acid precursor assembly including: a dry dialysis acid precursor composition including sodium chloride, a dry acid and a magnesium chloride 4.5-hydrate (MgCl2.4.5H2O), a calcium salt and at least one of a potassium salt, calcium salt and an anhydrous glucose, and a moisture-resistant container having a water vapor transmission rate less than 0.2 g/m2/d at 38° C./90% RH, wherein the dry dialysis acid precursor composition is sealed in the container.

Abstract: The present invention is directed to a transfer resistant and long wear cosmetic composition having a unique gel-like texture with good pickup, payoff, and spreadability properties, as well as a silky smooth feel containing: (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) water; (d) at least one volatile solvent; (e) at least one non-volatile solvent; (f) at least one water soluble surfactant; (f) at least one colorant; and (g) at least one oil absorbing powder.

Abstract: Provided are methods and compositions for locally increasing arterial diameter and providing local anesthesia in a subject. The methods include applying to a skin site of the subject a topical composition that includes a vasodilation agent and an anesthetic agent in a manner sufficient for locally increasing arterial diameter and providing local anesthesia in the subject. In some embodiments, the method includes inserting a cannula into an artery at the skin site of the subject. Also provided are topical compositions that find use in performing the subject methods.

Abstract: The present invention aims to provide a matrix-type solid preparation that has high-level release controllability for suppressing drug release in the upper gastrointestinal tract and accelerating drug release in the lower gastrointestinal tract, and that solves of all the above drawbacks caused by combining a plasticizer. The present invention provides a method for producing a matrix-type pharmaceutical solid preparation that contains: (a) a methacrylic acid-based enteric polymer; (b) a sugar and/or a sugar alcohol, and (c) tolvaptan.